Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Citius Oncology finalises McKesson deal for Lymphir distribution
Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults
Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults
This partnership will utilise Tempus’ de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus’ real-world dataset to focus on
The inhaler administers three active ingredients through a single device, known as single inhaler triple therapy (SITT), which has already received approval in nearly 50 countries. It combines
The collaboration aims to clarify the underlying mechanism of action of iQ-007. The results will assist in stratifying and identifying patients who may benefit from this astrocyte-targeted therapy,
The FDA has also approved BeOne’s application to participate in Project Orbis, an initiative that offers a framework for concurrent submission and oncology products review among collaborating health
ADCE-D01 is an antibody-drug conjugate (ADC) designed to target the urokinase plasminogen activator receptor-associated protein (uPARAP). Preclinical data indicate that ADCE-D01 exhibits anti-tumour activity in mesenchymal tumour models,
BAT2506 is a proposed biosimilar of golimumab, developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that specifically targets tumour necrosis factor alpha (TNF-α), a key pro-inflammatory
The funding will facilitate the establishment of Nilo’s laboratories in New York City, the growth of the team, and the advancement of preclinical programmes. Furthermore, the company has appointed
The funds will be used to advance the late-stage clinical development of the company’s leading candidate, inhaled AERO-007. This nebulised LABA/LAMA combination is being developed as a potential
Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with